Kelly E Dunn1, Bruna Brands2,3,4, David C Marsh5, George E Bigelow6. 1. Johns Hopkins University School of Medicine, Baltimore, MD, USA. kdunn9@jhmi.edu. 2. Health Canada, Ottawa, ON, Canada. 3. Centre for Addiction and Mental Health, Toronto, ON, Canada. 4. University of Toronto, Toronto, ON, Canada. 5. Northern Ontario School of Medicine, Sudbury, ON, Canada. 6. Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: This study compared the effects of the several doses of the opioid agonists heroin and hydromorphone across two routes of administration in humans. The goal was to guide development of human laboratory studies of opioid effects and inform subsequent injection pharmacotherapy trials of hydromorphone-assisted treatment. METHODS: A within-subject (N = 16), double-blind, double-dummy, placebo-controlled, evaluation of acute doses of heroin and hydromorphone was completed at four dose levels (placebo, low, medium, high) across two routes of administration (intravenous, subcutaneous) in non-physically dependent, opioid-experienced individuals. Subject and observer ratings, as well as physiological outcomes, were assessed. RESULTS: Within each route of administration, heroin and hydromorphone produced effects that were qualitatively similar on most variables across the doses examined. All effects were dose-dependent. The drugs produced different effects on VAS ratings of "Feels Like Heroin," a Heroin Identification Test, observer agonist ratings, and oxygen saturation levels. Drug-dependent differences emerged at the highest doses in all cases. Few significant main effects of Route were identified and their pattern was not uniform. Relative potency calculations across all subject, observer, and physiological outcomes that met analysis criteria revealed similar profiles and resulted in mean heroin:hydromorphone potencies of 3.35:1 and 2.88:1 for the intravenous and subcutaneous routes, respectively, and intravenous:subcutaneous potencies of 0.47:1 and 0.49:1 for heroin and hydromorphone, respectively. CONCLUSIONS:Hydromorphone produced similar subjective and physiological effects as heroin, but was more potent than heroin. The current findings support the use of hydromorphone as a model for heroin in human laboratory and clinical treatment studies, and help identify appropriate hydromorphone dose conversion ratios to produce effects qualitatively similar to heroin.
RCT Entities:
BACKGROUND: This study compared the effects of the several doses of the opioid agonists heroin and hydromorphone across two routes of administration in humans. The goal was to guide development of human laboratory studies of opioid effects and inform subsequent injection pharmacotherapy trials of hydromorphone-assisted treatment. METHODS: A within-subject (N = 16), double-blind, double-dummy, placebo-controlled, evaluation of acute doses of heroin and hydromorphone was completed at four dose levels (placebo, low, medium, high) across two routes of administration (intravenous, subcutaneous) in non-physically dependent, opioid-experienced individuals. Subject and observer ratings, as well as physiological outcomes, were assessed. RESULTS: Within each route of administration, heroin and hydromorphone produced effects that were qualitatively similar on most variables across the doses examined. All effects were dose-dependent. The drugs produced different effects on VAS ratings of "Feels Like Heroin," a Heroin Identification Test, observer agonist ratings, and oxygen saturation levels. Drug-dependent differences emerged at the highest doses in all cases. Few significant main effects of Route were identified and their pattern was not uniform. Relative potency calculations across all subject, observer, and physiological outcomes that met analysis criteria revealed similar profiles and resulted in mean heroin:hydromorphone potencies of 3.35:1 and 2.88:1 for the intravenous and subcutaneous routes, respectively, and intravenous:subcutaneous potencies of 0.47:1 and 0.49:1 for heroin and hydromorphone, respectively. CONCLUSIONS:Hydromorphone produced similar subjective and physiological effects as heroin, but was more potent than heroin. The current findings support the use of hydromorphone as a model for heroin in human laboratory and clinical treatment studies, and help identify appropriate hydromorphone dose conversion ratios to produce effects qualitatively similar to heroin.
Authors: Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis Journal: CMAJ Date: 2012-03-12 Impact factor: 8.262
Authors: Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby Journal: Am J Public Health Date: 2012-11-15 Impact factor: 9.308
Authors: Eugenia Oviedo-Joekes; Daphne Guh; Suzanne Brissette; Kirsten Marchand; Scott MacDonald; Kurt Lock; Scott Harrison; Amin Janmohamed; Aslam H Anis; Michael Krausz; David C Marsh; Martin T Schechter Journal: JAMA Psychiatry Date: 2016-05-01 Impact factor: 21.596
Authors: Andrew S Huhn; Eric C Strain; George E Bigelow; Michael T Smith; Robert R Edwards; D Andrew Tompkins Journal: Anesthesiology Date: 2019-01 Impact factor: 7.892
Authors: Kelly E Dunn; Frederick S Barrett; Bruna Brands; David C Marsh; George E Bigelow Journal: Drug Alcohol Depend Date: 2019-10-28 Impact factor: 4.492
Authors: Kelly E Dunn; Cecilia L Bergeria; Andrew S Huhn; Traci J Speed; Chung Jung Mun; Ryan Vandrey; Claudia M Campbell Journal: Neuropsychopharmacology Date: 2021-04-20 Impact factor: 7.853